Abstract

TPS5599Background: Platinum-based CT is the treatment of choice for OC patients (pts) with TFIp > 6 months suitable for platinum. Niraparib is an oral PARP inhibitor that significantly prolongs the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
ENGOT-Ov41/GEICO-69-O/ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp) >6 months.
Antonio González-Martín ... Florian Heitz
Journal of Clinical Oncology | VOL. 37
Antonio González-Martín, et. al.Antonio González-Martín ... Florian Heitz
20 May 2019
PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?
U.A Matulonis ... B.J Monk
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 28
U.A Matulonis, et. al.U.A Matulonis ... B.J Monk
01 Mar 2017
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
Antonio Gonzalez Martin ... Mihai Meirovitz
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. 31
Antonio Gonzalez Martin, et. al.Antonio Gonzalez Martin ... Mihai Meirovitz
14 Dec 2020
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness
A Tutt
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 29
A TuttA Tutt
01 Jan 2018
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
Alexios Matikas ...
Journal of Clinical Oncology | VOL. -
Alexios Matikas, et. al.Alexios Matikas ...
17 Jul 2024
Lymphoma Classifications, How to Develop a Future Unified Taxonomy.
Elias Campo ... Reiner Siebert
Journal of Clinical Oncology | VOL. -
Elias Campo, et. al.Elias Campo ... Reiner Siebert
17 Jul 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.
Brian C Shaffer ... Monzr M Al Malki
Journal of Clinical Oncology | VOL. -
Brian C Shaffer, et. al.Brian C Shaffer ... Monzr M Al Malki
17 Jul 2024
Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
Steven J Katz ... Allison W Kurian
Journal of Clinical Oncology | VOL. -
Steven J Katz, et. al.Steven J Katz ... Allison W Kurian
15 Jul 2024
View more papers